Could an HIV drug protect new lungs after transplant?
NCT ID NCT06853223
First seen Jan 31, 2026 · Last updated Jun 13, 2026 · Updated 20 times
Summary
This study tests whether Maraviroc, a drug already approved for HIV, can prevent a serious lung injury called primary graft dysfunction (PGD) after a lung transplant. PGD is a major cause of death in the first year after transplant, and there are no approved treatments for it. About 120 adults getting a double lung transplant will receive either Maraviroc or a placebo for 3 days after surgery. Researchers will compare how many develop severe PGD and how well they recover.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER CELL MEDIATED IMMUNITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.